
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Brand Name | Status | Last Update |
|---|---|---|
| aristada | New Drug Application | 2025-01-28 |
| aristada initio | New Drug Application | 2025-01-28 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Aripiprazole Lauroxil, Aristada, Alkermes Inc | |||
| 11273158 | 2039-04-06 | U-543 | |
| 9452131 | 2035-03-19 | U-2402 | |
| 9526726 | 2035-03-19 | DP | |
| 10238651 | 2035-03-19 | U-2402 | |
| 10813928 | 2035-03-19 | U-2402, U-2983 | |
| 11406632 | 2035-03-19 | U-2402 | |
| 9193685 | 2033-10-24 | DP | U-543 |
| 11097006 | 2033-10-24 | DP | U-764 |
| 9034867 | 2032-11-07 | DP | U-543 |
| 10226458 | 2032-03-19 | U-543 | |
| 8431576 | 2030-10-26 | DP | |
| 8796276 | 2030-06-24 | U-543 | |
| 10112903 | 2030-06-24 | DP | U-543 |
| Aripiprazole Lauroxil, Aristada Initio Kit, Alkermes Inc | |||
| 10016415 | 2035-09-08 | DP | |
| 10688091 | 2035-08-17 | DP | |
| 10849894 | 2035-08-17 | U-543 | |
| 11154552 | 2035-08-17 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | — | 4 | 3 | 1 | 11 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | 1 | — | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | 1 | — | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
| Drug common name | Aripiprazole lauroxil |
| INN | aripiprazole |
| Description | Aripiprazole lauroxil is a dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. It has a role as a H1-receptor antagonist, a second generation antipsychotic, a serotonergic agonist and a prodrug. It is a dodecanoate ester, a quinolone, a dichlorobenzene, a N-arylpiperazine, a N-alkylpiperazine, an aromatic ether and a delta-lactam. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21 |
| PDB | — |
| CAS-ID | 1259305-29-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2219425 |
| ChEBI ID | — |
| PubChem CID | 49831411 |
| DrugBank | DB14185 |
| UNII ID | 82VFR53I78 (ChemIDplus, GSRS) |





